# Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.

> **NCT06356922** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nantes University Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Acute Leukemia

## Interventions

- **DRUG:** Experimental drug [177Lu]Lu-PentixaTher

## Key facts

- **NCT ID:** NCT06356922
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2027-10-22
- **Final completion:** 2027-10-22
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356922, "Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06356922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*